Gitelman Syndrome

Gitelman Syndrome β€” scientific infographic poster

Most common inherited renal tubular disorder (prevalence ~1:40,000); autosomal recessive; SLC12A3 mutation causing defective thiazide-sensitive NaCl cotransporter (NCC) in distal convoluted tubule (DCT).

Table of Contents

  1. Overview and Pathophysiology
  2. The Biochemical Tetrad
  3. Clinical Presentation
  4. Diagnosis and Work-Up
  5. Differentiating Gitelman from Bartter Syndrome
  6. Cardiovascular Risks and QT Prolongation
  7. Treatment and Management
  8. Prognosis and Quality of Life
  9. Long-Term Outcomes in 587 Patients
  10. Key Research Papers
  11. Connections
πŸ”ƒ Interactive Visualization The Sodium–Potassium Pump β€” why you have a voltage Run the pump that gives every cell its charge β€” three sodium out, two potassium in, on Mg-ATP β€” then drop the magnesium and see exactly why low potassium refuses to correct. Launch →

Overview and Pathophysiology

Gitelman syndrome is the most common inherited salt-losing tubulopathy, caused by loss-of-function mutations in SLC12A3, which encodes the thiazide-sensitive NaCl cotransporter (NCC) in the distal convoluted tubule (DCT). The DCT reabsorbs approximately 5–7% of filtered NaCl. NCC inactivation leads to a cascade of downstream electrolyte disturbances:

  1. Salt wasting β†’ volume depletion β†’ activation of the renin–angiotensin–aldosterone system (RAAS) β†’ secondary aldosteronism β†’ increased activity of the epithelial sodium channel (ENaC) β†’ K+ and H+ excretion β†’ hypokalemia + metabolic alkalosis
  2. Reduced luminal Na+ β†’ increased Na/Ca exchanger activity on basolateral membrane β†’ increased intracellular Ca2+ pumped out β†’ net hypocalciuria
  3. Impaired Mg2+ reabsorption via TRPM6 (Mg2+ channel in DCT, NCC-dependent) β†’ hypomagnesemia

The resulting phenotype closely mimics chronic thiazide diuretic use β€” this pharmacological parallel is central to understanding the mechanism and guides both diagnosis and treatment.

Inheritance is autosomal recessive. Heterozygous carriers are usually asymptomatic but may have mild electrolyte changes. More than 400 pathogenic variants in SLC12A3 have been identified; compound heterozygosity is common.

Back to Table of Contents

The Biochemical Tetrad

Gitelman syndrome is defined by four characteristic laboratory findings that together constitute the diagnostic biochemical profile:

  1. Hypokalemia: typically 2.5–3.2 mEq/L, with elevated urine potassium (inappropriate kaliuresis despite low serum K+, driven by aldosterone). The urinary K/Cr ratio is elevated, confirming renal potassium wasting rather than extrarenal losses.
  2. Metabolic alkalosis: elevated HCO3- (usually 28–36 mEq/L), arising from aldosterone-driven H+ secretion and from contraction alkalosis secondary to volume depletion.
  3. Hypomagnesemia: serum Mg2+ <0.7 mmol/L; caused by impaired TRPM6-mediated Mg2+ reabsorption in the DCT. Present in approximately 70% of patients. Clinically important because hypomagnesemia causes neuromuscular irritability and potentiates cardiac arrhythmias independent of potassium.
  4. Hypocalciuria: urine calcium-to-creatinine ratio usually below 0.2 mmol/mmol, and 24-hour urine calcium rarely above 0.5 mg/kg/day (Knoers and Levtchenko, 2008). This is the KEY DISTINGUISHING FEATURE from Bartter syndrome, which produces hypercalciuria. The mechanism: NCC inactivation increases basolateral Na/Ca exchange, enhancing transcellular Ca2+ reabsorption.

All four findings, combined with normal blood pressure, elevated plasma renin activity, and elevated aldosterone, constitute the complete diagnostic biochemical profile of Gitelman syndrome.

Back to Table of Contents

Clinical Presentation

Onset typically occurs in late childhood, adolescence, or adulthood β€” unlike Bartter syndrome, which often presents in infancy or early childhood. A substantial proportion of patients are diagnosed incidentally when routine laboratory panels reveal unexplained hypokalemia.

Symptomatic patients commonly report:

Gitelman syndrome does not cause polyhydramnios (excess amniotic fluid) or nephrocalcinosis, both of which are associated with antenatal Bartter syndrome.

Back to Table of Contents

Diagnosis and Work-Up

No single test diagnoses Gitelman syndrome β€” confirmation requires integration of clinical presentation, biochemical pattern, and genetic testing. A systematic approach:

  1. Step 1 β€” Confirm the biochemical tetrad: Serum K+, Mg2+, bicarbonate, and spot urine calcium-to-creatinine ratio (or 24-hour urine calcium). Hypocalciuria on a random urine specimen (Ca/Cr usually <0.2 mmol/mmol) is strongly suggestive.
  2. Step 2 β€” Confirm secondary hyperaldosteronism: Plasma renin activity (elevated) and serum aldosterone (elevated) in the absence of hypertension distinguishes Gitelman/Bartter from primary hyperaldosteronism (which suppresses renin).
  3. Step 3 β€” Exclude diuretic use: Urine thiazide and loop diuretic screen by mass spectrometry. Surreptitious diuretic use is the most important mimicker.
  4. Step 4 β€” Genetic testing: SLC12A3 sequencing identifies pathogenic variants in approximately 85–90% of clinically diagnosed cases. Next-generation sequencing panels covering SLC12A3 plus other tubulopathy genes are preferred. Some patients are compound heterozygotes with one allele carrying a deep intronic or splice-site variant.
  5. Step 5 β€” If SLC12A3 negative: Consider CLCNKB sequencing (Bartter Type III / mixed phenotype). Some CLCNKB mutations produce a Gitelman-like phenotype including hypocalciuria.

Historical note: The thiazide response test (thiazide causes less natriuresis in Gitelman patients than in healthy controls because the target NCC is already non-functional) was used prior to widespread genetic testing. It has been largely replaced by genetic analysis but remains a conceptual teaching tool.

Back to Table of Contents

Differentiating Gitelman from Bartter Syndrome

Gitelman and Bartter syndromes share hypokalemia, metabolic alkalosis, normal blood pressure, and elevated renin/aldosterone. The key distinguishing features are:

Feature Gitelman Syndrome Bartter Syndrome (Types I/II/IV) Bartter Type III
Urine calcium Hypocalciuria (hallmark) Hypercalciuria Variable
Serum magnesium Low (~70% of patients) Usually normal Usually normal
Age of onset Adolescence/adulthood Neonatal/early childhood Childhood/adolescence
Clinical severity Mild; often incidental Severe; growth failure Moderate
Nephrocalcinosis Absent Present (antenatal types) Less common
Polyhydramnios Absent Present (Types I/II/IV) Absent
Causative gene SLC12A3 (DCT NCC) SLC12A1, KCNJ1, BSND (thick ascending limb, TAL) CLCNKB (TAL/DCT)

Both conditions share elevated urine chloride (confirming renal Cl wasting rather than vomiting-related alkalosis, which causes low urine Cl). The hypocalciuria in Gitelman is arguably the single most reliable bedside biochemical discriminator.

Back to Table of Contents

Cardiovascular Risks and QT Prolongation

Although Gitelman syndrome is generally a mild condition, its electrolyte disturbances carry real cardiac risk that deserves attention in clinical management:

Hypokalemia and QT prolongation: K+ channels (particularly IKr, encoded by KCNH2) are responsible for phase 3 cardiac repolarization. When serum K+ falls, IKr current decreases, delaying repolarization and prolonging the QTc interval. A QTc >450 ms (males) or >460 ms (females) indicates elevated risk.

How often the QT is prolonged: Knoers and Levtchenko (2008) report that in about 50% of people with Gitelman syndrome the QT interval on the electrocardiogram is slightly to moderately prolonged, but in the great majority this is not linked to clinically relevant heart rhythm problems. Sudden cardiac arrest has been reported in only a few patients, and the authors describe heart screening in such cases to look for other triggers or underlying conditions.

Hypomagnesemia: Mg2+ stabilizes cardiac ion channels. Hypomagnesemia independently prolongs QT and, more dangerously, predisposes to early afterdepolarizations β€” the trigger for torsades de pointes (TdP), a potentially fatal polymorphic ventricular tachycardia. The combination of low potassium and low magnesium is synergistically arrhythmogenic.

Drug interactions: Many commonly prescribed medications prolong QT (antipsychotics including haloperidol and quetiapine; macrolide antibiotics; fluoroquinolones; methadone; ondansetron). These drugs carry substantially increased arrhythmia risk in patients with uncorrected Gitelman electrolyte disturbances. For this reason, medication lists are checked for QT-prolonging drugs, and electrolytes are corrected before such drugs are started.

Clinical monitoring: electrocardiogram (ECG) is recommended at baseline and during acute illness (when dehydration and vomiting can acutely worsen low potassium and low magnesium). Routine electrocardiogram monitoring at annual follow-up is reasonable in patients with persistent hypomagnesemia.

Treatment priority: In usual care, magnesium is replaced before or together with potassium. A 2007 review by Huang and Kuo explains why: magnesium deficiency makes low potassium worse and harder to correct with potassium alone. In the kidney cells that release potassium into the urine, magnesium inside the cell normally acts as a brake on the potassium channel called ROMK (renal outer medullary potassium channel). When magnesium inside the cell falls, the brake comes off, the channel lets more potassium out into the urine, and part of any potassium supplement is lost. The review adds that magnesium deficiency alone does not always cause low potassium; more sodium reaching the end of the kidney tubule or high aldosterone levels may be needed for the extra loss, and aldosterone is raised in Gitelman syndrome (see the tetrad above).

Back to Table of Contents

Treatment and Management

Treatment targets: serum K+ >3.5 mEq/L and serum Mg2+ >0.7 mmol/L. Complete normalization is often unachievable given ongoing renal wasting, but symptom control is the realistic goal.

1. Magnesium Supplementation (First Priority)

2. Potassium Supplementation

3. Dietary Modifications

4. Aldosterone Antagonists

5. Amiloride

6. Indomethacin

The only randomised comparison: In a 2015 crossover trial by Blanchard and colleagues, 30 patients took slow-release indomethacin 75 mg, eplerenone 150 mg and amiloride 20 mg once daily, 6 weeks each, on top of unchanged potassium and magnesium supplements. Blood potassium started at 2.8 mmol/L and rose by 0.38 mmol/L with indomethacin, 0.19 mmol/L with amiloride and 0.15 mmol/L with eplerenone; 15 patients reached normal potassium (6 on indomethacin, 6 on amiloride, 3 on eplerenone). Indomethacin worked best but lowered kidney filtration (eGFR). Eight patients stopped early: 6 because of stomach and gut intolerance of indomethacin and 2 because of low blood pressure on eplerenone. Amiloride and eplerenone increased sodium loss.

Back to Table of Contents

Prognosis and Quality of Life

The overall prognosis of Gitelman syndrome is generally favorable. Most patients lead full, productive lives with appropriate electrolyte supplementation.

Acute decompensation risk: gastrointestinal illnesses involving vomiting or diarrhea can precipitate acute crises β€” additional fluid and electrolyte losses on top of the chronic baseline deficit can drive K+ below 2.0 mEq/L and Mg2+ below 0.4 mmol/L, with risk of muscle paralysis, tetany, and arrhythmia. Muscle weakness or paralysis, tetany (muscle spasms) and an irregular or racing heartbeat during such an illness are signs that hospitals treat as urgent.

Long-term renal function: Generally preserved. Gitelman syndrome does not cause nephrocalcinosis, and structural renal damage is not a characteristic feature. Renal function is checked periodically to detect unrelated comorbid renal disease.

Chondrocalcinosis: Chronic hypomagnesemia may contribute to calcium pyrophosphate (CPP) crystal deposition in cartilage, causing joint pain and episodic pseudogout. This can significantly impact quality of life and may require rheumatologic co-management.

Cardiac outcomes: Low risk with maintained electrolytes. In people whose potassium or magnesium stays low, QT-prolonging drugs add to the rhythm risk described above, and closer heart monitoring is usual.

Pregnancy: Requires close electrolyte monitoring throughout gestation. Electrolyte disturbances may worsen due to volume expansion and increased renal demands. Neonatal outcomes are generally good; affected fetuses do not exhibit the polyhydramnios or prematurity seen in antenatal Bartter syndrome.

Annual monitoring: Knoers and Levtchenko (2008) describe yearly outpatient follow-up, generally by kidney specialists. Tests commonly listed:

Back to Table of Contents

Long-Term Outcomes in 587 Patients

A 2025 survey (Wieërs and colleagues) collected data from doctors in Europe on 587 people with Gitelman syndrome in 13 countries (25% of them children) and compared patients in the Netherlands with the general population:

Back to Table of Contents

Key Research Papers

  1. β€” Simon DB et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet. 1996. — PubMed PMID: 8528245
  2. β€” Lemmink HH et al. Novel mutations in the thiazide-sensitive NaCl cotransporter gene in patients with Gitelman syndrome with predominant localization to the C-terminal domain. Kidney Int. 1998. — PubMed PMID: 9734597
  3. β€” Knoers NV, Levtchenko EN. Gitelman syndrome. Orphanet J Rare Dis. 2008. — PubMed PMID: 18667063
  4. β€” Jiang L et al. Clinical severity of Gitelman syndrome determined by serum magnesium. Am J Nephrol. 2014. — PubMed PMID: 24776766
  5. β€” Walsh PR et al. Clinical and diagnostic features of Bartter and Gitelman syndromes. Clin Kidney J. 2018. — PubMed PMID: 29942493
  6. β€” Cruz DN et al. Gitelman's syndrome revisited: an evaluation of symptoms and health-related quality of life. Kidney Int. 2001. — PubMed PMID: 11168953
  7. β€” Vargas-Poussou R et al. Spectrum of mutations in Gitelman syndrome. J Am Soc Nephrol. 2011. — PubMed PMID: 21415153
  8. β€” Blanchard A et al. Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2017. — PubMed PMID: 28003083
  9. β€” Schlingmann KP et al. Salt wasting and deafness resulting from mutations in two chloride channels. N Engl J Med. 2004. — PubMed PMID: 15044642
  10. β€” Riveira-Munoz E et al. Transcriptional and functional analyses of SLC12A3 mutations. J Am Soc Nephrol. 2007. — PubMed PMID: 17329572
  11. β€” Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol. 2007. — PubMed PMID: 17804670
  12. β€” Blanchard A et al. Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome. J Am Soc Nephrol. 2015. — PubMed PMID: 25012174
  13. β€” Wieërs MLAJ et al. Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome. Kidney Int Rep. 2025. — PubMed PMID: 41278357

Back to Table of Contents

Connections

Back to Table of Contents